Clinical Trials Sponsored by Cidara Therapeutics Inc.

Total 3029 results

Cidara Therapeutics Inc.

Completed

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

Healthy

United States
Cidara Therapeutics Inc.

Recruiting

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT)

Mycoses | Candidemia | Fungemia | Fungal Infection | Invasive Candidiasis | Invasive Fungal Disease | Pneumocystis | Mold Infection | Prophylaxis of Invasive Fungal Infections | Aspergillus

United States, Germany, France, Belgium, Canada, Italy, Spain, United Kingdom, Turkey, Switzerland
Cidara Therapeutics Inc.

Completed

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)

Mycoses | Candidemia | Fungal Infection | Invasive Candidiases

United States, Israel, Spain, Korea, Republic of, Taiwan, Singapore, Thailand, Australia, China, Turkey, Belgium, Germany, France, Argentina, Bulgaria, Colombia, Greece, Italy
Cidara Therapeutics Inc.

Completed

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
Cidara Therapeutics Inc.

Completed

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (STRIVE)

Mycoses | Candidemia | Fungemia | Fungal Infection | Invasive Candidiasis

United States, Spain, Belgium, Russian Federation, Greece, Bulgaria, Canada, Hungary, Italy, Romania
Cidara Therapeutics Inc.

Completed

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
Cidara Therapeutics Inc.

Completed

An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects

Healthy

United States
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Healthy

United States
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults

Influenza

United Kingdom
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Active, not recruiting

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Healthy

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Pruritus | Notalgia Paresthetica

United States, Canada
Cara Therapeutics, Inc.

Approved for marketing

Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

Uremic Pruritus
Cara Therapeutics, Inc.

Completed

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-2)

Uremic Pruritus

United States, Canada, Czechia, Australia, Germany, Hungary, Korea, Republic of, New Zealand, Poland, Taiwan, United Kingdom
Cara Therapeutics, Inc.

Completed

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

Post Abdominal Surgery Pain

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

Postoperative Pain

United States
Cara Therapeutics, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Pruritus | Notalgia Paresthetica

United States, Poland, Spain, Canada, Germany
Cara Therapeutics, Inc.

Recruiting

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KIND-1)

Pruritus | Atopic Dermatitis

United States
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Cholestatic Pruritus

United States
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada
Cara Therapeutics, Inc.

Completed

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

Arthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Cara Therapeutics, Inc.

Completed

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

Healthy

United States
Cara Therapeutics, Inc.

Completed

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Osteoarthritis

United States
Cara Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Pruritus | Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Acute Pain

United States
Cara Therapeutics, Inc.

Completed

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

Acute Pain

United States
Cara Therapeutics, Inc.

Recruiting

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States, Korea, Republic of, Australia, Bulgaria, Germany, Hungary, Italy, Poland, Romania, Spain, Argentina, Brazil, Mexico
Cara Therapeutics, Inc.

Completed

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

Hemodialysis

United States
Cara Therapeutics, Inc.

Completed

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States, Czechia, Hungary, Poland
Cara Therapeutics, Inc.

Completed

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States, Puerto Rico
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

Healthy | Hemodialysis

United States
Vidara Therapeutics Research Ltd

Unknown

Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers (FLS)

Adverse Effects in the Therapeutic Use of Interferon

United States
DARA Therapeutics

Completed

Neuropathic Pain in Patients With Cancer

Neuropathic Pain

United States, Puerto Rico
University of Cologne
Pfizer; F2G Biotech GmbH; Basilea Pharmaceutica; Cidara Therapeutics Inc.; Matinas...

Recruiting

FungiScope - A Global Emerging Fungal Infection Registry (FungiScope)

Invasive Fungal Disease

Germany
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Therapeutics, Inc.

Completed

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

Scalp Psoriasis

United States
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States

3

Subscribe